Cogent Biosciences released quarterly earnings results that came in below consensus expectations on an earnings-per-share ...

This is read by an automated voice. Please report any issues or inconsistencies here. Animation is the backbone of the film industry, boosting the global box office year after year. But such ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

The Pixar Era kicked off 30 years ago with the first installment of the popular franchise. It’s given us countless hits, but something has also been lost. By Maya Phillips There are so many ways of ...

NEW YORK, Nov 12 (Reuters) - The U.S. Food and Drug Administration can approve new personalized treatments for rare and deadly genetic diseases based on data from a handful of patients, two of the ...

Nov 4 (Reuters) - Drug developer Compass Pathways (CMPS.O), opens new tab said on Tuesday it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways, which ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...